Back to top
more

AC Immune (ACIU)

(Real Time Quote from BATS)

$2.40 USD

2.40
21,459

+0.02 (0.84%)

Updated Apr 19, 2024 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACIU

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

AC Immune [ACIU]

Reports for Purchase

Showing records 1 - 20 ( 62 total )

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 1

03/15/2024

Company Report

Pages: 7

Preclinical AD Trial Analysis Needs Different Approach to Understand Treatment Effects

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 2

03/07/2024

Industry Report

Pages: 3

Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 3

02/01/2024

Daily Note

Pages: 4

AC Immune Shifts Gear, Focuses on Three Active Immunization Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 4

11/13/2023

Company Report

Pages: 5

Expecting an Active Dose That Shows Signs of Amyloid Reduction in ABATE; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 5

11/06/2023

Company Report

Pages: 7

All Eyes on ACI-24.060’s Safety, Immunogenicity, and PET Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 6

10/26/2023

Industry Report

Pages: 4

Key Takeaways from CTAD 2023¯Implications for the Next Generation Anti-AmyloidsThis report contains brief updates on the following: ABOS, ACIU, ALEC, BIIB, DNLI, PRTA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 7

08/07/2023

Company Report

Pages: 7

Abeta PET and Alpha-Synuclein SAA Might Help Understand Vaccine Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 8

06/28/2023

Daily Note

Pages: 4

Expectations from the Phase 1b/2 ABATE Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 9

05/01/2023

Company Report

Pages: 6

Abeta PET Data Might Determine future of ABATE; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 10

04/19/2023

Daily Note

Pages: 5

KOL Webinar Reflects on the Current Trends in Biomarker Development in CNS Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 11

03/30/2023

Industry Report

Pages: 4

NfL Might be the Best Predictor of Motor Progression in PD-Takeaways from AD/PD 2023 Gothenburg

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 12

03/17/2023

Company Report

Pages: 7

Thoughts on the Anti Abeta Vaccine ACI-24.060; Reit. Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 13

12/01/2022

Daily Note

Pages: 4

Future of AD Therapy Might be Vaccines-Takeaways from ACI-35.030 Data Readout at CTAD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 14

10/31/2022

Company Report

Pages: 7

Passive Anti-Abeta Immunotherapies are Encouraging for Abeta Vaccines; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 15

10/20/2022

Industry Report

Pages: 5

Seed for Successful PD Trial Outcome is Sown¯Takeaways From the 2022 PD Therapeutic Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 16

09/28/2022

Industry Report

Pages: 5

The Beginning of an Era of Anti-Amyloids and Combination Therapies in Alzheimer''s Disease

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 17

09/16/2022

Industry Report

Pages: 4

The Pubmed Times¯Focusing on the Need to Pull Down Toxic Oligomers

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 18

08/25/2022

Daily Note

Pages: 6

KOL Webinar Showcases the Strength of Vaccines Over Passive Immunization for AD and PD Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 19

08/04/2022

Industry Report

Pages: 5

Thoughts on API ADAD Data Readout-Implications for Anti-Abeta Therapy Landscape

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: AC Immune

Industry: Medical - Biomedical and Genetics

Record: 20

07/29/2022

Company Report

Pages: 7

Reflections on the Upcoming ACI-24.060 Phase 1b Interim Data Readout in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party